Abatacept: A Promising Repurposed Solution for Myocardial Infarction-Induced Inflammation in Rat Models

Figure 8

Effect of Abatacept on MAPK signaling pathway proteins in IR injury model of myocardial infarction. (a) P38, p-P38, and their ratio (p-P38/P38); (b) JNK, p-JNK, and their ratio (p-JNK/JNK); (c) ERK 1/2/P-ERK 1/2; (d) downstream pathway NF-κB; (e) cytokine levels [TNF/IL-6 (e: A–B)]. Data are expressed as mean ± SEM; n = 3 in each group. IR-C, ischemia-reperfusion control; Telmi10+IR, telmisartan 10 mg/kg+ischemia reperfusion; ABT5+IR, Abatacept 5 mg/kg+ischemia reperfusion; MAPK, mitogen-activated protein kinase; JNK, c-jun N-terminal Kinase; ERK, extracellular signal-regulated kinase; NF-κB, nuclear factor kappa B; TNF, tumor necrosis factor, IL-6: interleukin-6.

(a)

(b)

(c)

(d)

(e)